Today, at the 11th Annual Meeting of the American Society of Breast Surgeons, Agendia, a world leader in molecular cancer diagnostics, announced that Breast Cancer Research and Treatment has published an important study demonstrating the benefit of adjuvant chemotherapy for patients with a high-risk of breast cancer recurrence according to the MammaPrint test. The ASBS meeting takes places April 28 - May 2, 2010, at the Bellagio in Las Vegas, where you can meet the Agendia team at booth # 314.
The study evaluated 541 patients who were classified as either high-risk or low-risk for breast cancer recurrence using the 70-gene MammaPrint signature. For patients classified as high-risk, the addition of chemotherapy to hormone treatment showed significant survival benefit and meaningful clinical benefit. This benefit was not significant in low-risk patients, who were at such reduced risk for recurrence and cancer-related death, that adding chemotherapy did not appear to be clinically meaningful.
"It is important to provide patients with individualized treatment regimens. These findings help further this aim and confirm MammaPrint's predictive capabilities in determining which patients are likely to benefit from chemotherapy," commented Richard Bender, MD, FACP, Chief Medical Officer of Agendia and study co-author.
The study titled, "The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer," can be accessed at http://www.springer.com/medicine/oncology/journal/10549.
Novel drug delivery system aims to prevent hearing loss from cisplatin chemotherapy